{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "section-532", "type": "clause", "offset": [29, 42]}], "snippet": "has the meaning set forth in Section 5.3.2 (Transition).", "samples": [{"hash": "fyyY1aCKvdq", "uri": "/contracts/fyyY1aCKvdq#transition-activities", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.8453121185, "published": true}, {"hash": "d4YNOZGiWoQ", "uri": "/contracts/d4YNOZGiWoQ#transition-activities", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.8398361206, "published": true}, {"hash": "6A88nyJpxXr", "uri": "/contracts/6A88nyJpxXr#transition-activities", "label": "Collaboration Agreement (Voyager Therapeutics, Inc.)", "score": 26.7686519623, "published": true}], "size": 12, "hash": "511770d9e0b4f769902bd6d6b10a072e", "id": 1}, {"snippet_links": [{"key": "section-81", "type": "clause", "offset": [29, 40]}], "snippet": "has the meaning set forth in Section 8.1.", "samples": [{"hash": "cjhd3M6iQaq", "uri": "/contracts/cjhd3M6iQaq#transition-activities", "label": "Joint Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 32.5756340027, "published": true}, {"hash": "hZ6qcOoalg7", "uri": "/contracts/hZ6qcOoalg7#transition-activities", "label": "Joint Development and Commercialization Agreement (CRISPR Therapeutics AG)", "score": 32.3182754517, "published": true}], "size": 5, "hash": "a66384a736a0b9448bac33a8971c6f5a", "id": 2}, {"snippet_links": [{"key": "the-activities", "type": "clause", "offset": [6, 20]}, {"key": "by-medimmune", "type": "clause", "offset": [37, 49]}, {"key": "to-transfer", "type": "clause", "offset": [77, 88]}, {"key": "licensed-technology", "type": "clause", "offset": [93, 112]}, {"key": "licensed-compound", "type": "definition", "offset": [121, 138]}, {"key": "to-licensee", "type": "definition", "offset": [139, 150]}, {"key": "set-out", "type": "definition", "offset": [154, 161]}], "snippet": "means the activities to be conducted by MedImmune and applicable timeframes, to transfer the Licensed Technology and the Licensed Compound to Licensee as set out in Schedule 1.104.", "samples": [{"hash": "hziIcnmiSnu", "uri": "/contracts/hziIcnmiSnu#transition-activities", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "hO7GMiXBP6q", "uri": "/contracts/hO7GMiXBP6q#transition-activities", "label": "License Agreement (Kiniksa Pharmaceuticals, Ltd.)", "score": 29.3641338348, "published": true}, {"hash": "l4x10KSCpvd", "uri": "/contracts/l4x10KSCpvd#transition-activities", "label": "License Agreement (Kiniksa Pharmaceuticals, Ltd.)", "score": 29.3175907135, "published": true}], "size": 4, "hash": "95895278a491df5302a08e0179f536d6", "id": 3}, {"snippet_links": [{"key": "the-provider", "type": "definition", "offset": [30, 42]}, {"key": "from-the-effective-date", "type": "clause", "offset": [64, 87]}, {"key": "services-start-date", "type": "definition", "offset": [95, 114]}, {"key": "to-ensure", "type": "clause", "offset": [115, 124]}, {"key": "provide-the", "type": "clause", "offset": [144, 155]}], "snippet": "means all acts or things that the Provider will do or undertake from the Effective Date to the Services Start Date to ensure that it is able to provide the Services from the Services Start Date.", "samples": [{"hash": "gJpjOJ6eomS", "uri": "/contracts/gJpjOJ6eomS#transition-activities", "label": "Memorandum of Understanding", "score": 26.8412055969, "published": true}, {"hash": "3655R4z4E5W", "uri": "/contracts/3655R4z4E5W#transition-activities", "label": "Memorandum of Understanding", "score": 26.8412055969, "published": true}, {"hash": "j2YTYLmHPlJ", "uri": "/contracts/j2YTYLmHPlJ#transition-activities", "label": "Memorandum of Understanding", "score": 26.7097873688, "published": true}], "size": 4, "hash": "e921d338080acb5a908b2b84afe2d9b8", "id": 4}, {"snippet_links": [{"key": "the-activities", "type": "clause", "offset": [6, 20]}, {"key": "set-out", "type": "definition", "offset": [21, 28]}], "snippet": "means the activities set out in Exhibit 16.2.5.", "samples": [{"hash": "hKcc7E0411Q", "uri": "/contracts/hKcc7E0411Q#transition-activities", "label": "Collaboration & License Agreement (Aurinia Pharmaceuticals Inc.)", "score": 32.6249160767, "published": true}, {"hash": "9z6Ua8rn7Tc", "uri": "https://www.auriniapharma.com/investors-and-media/sec-filings/all-sec-filings/content/0001628280-21-017175/0001628280-21-017175.pdf", "label": "www.auriniapharma.com", "score": 16.4494934082, "published": false}, {"hash": "bzFx6cblRQd", "uri": "https://ir.auriniapharma.com/all-sec-filings/content/0001628280-21-017175/0001628280-21-017175.pdf", "label": "ir.auriniapharma.com", "score": 10.8124570847, "published": false}], "size": 3, "hash": "a5cca70f917f3359117dfe14e3c05228", "id": 5}, {"snippet_links": [{"key": "scope-of", "type": "clause", "offset": [44, 52]}, {"key": "transition-plan", "type": "definition", "offset": [53, 68]}], "snippet": "has the meaning set forth in Section 2.2.1 (Scope of Transition Plan).", "samples": [{"hash": "iooKKr1lGGD", "uri": "/contracts/iooKKr1lGGD#transition-activities", "label": "Aln At3 Global License Terms (Alnylam Pharmaceuticals, Inc.)", "score": 30.5934295654, "published": true}, {"hash": "dd1LNSkE0QE", "uri": "/contracts/dd1LNSkE0QE#transition-activities", "label": "Global License Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 29.3367557526, "published": true}, {"hash": "7hb4QWR0AAI", "uri": "/contracts/7hb4QWR0AAI#transition-activities", "label": "Exclusive License Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 29.3367557526, "published": true}], "size": 3, "hash": "ebdfcfdc3d89f566979d14653900b650", "id": 6}, {"snippet_links": [{"key": "section-22", "type": "clause", "offset": [29, 40]}], "snippet": "has the meaning set forth in Section 2.2 (Transition).", "samples": [{"hash": "b65cQfGV73d", "uri": "/contracts/b65cQfGV73d#transition-activities", "label": "Master Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 25.3504447937, "published": true}], "size": 3, "hash": "d6dea2bad93d67c574f7057f1bbbddd4", "id": 7}, {"snippet_links": [{"key": "the-activities", "type": "clause", "offset": [6, 20]}, {"key": "transition-plan", "type": "definition", "offset": [64, 79]}], "snippet": "means the activities to be conducted by 7&8 as set forth in the Transition Plan.", "samples": [{"hash": "komvCthxGS7", "uri": "/contracts/komvCthxGS7#transition-activities", "label": "Exclusive Collaboration Agreement (Eikon Therapeutics, Inc.)", "score": 37.0219028063, "published": true}, {"hash": "agTp2dRsUhH", "uri": "/contracts/agTp2dRsUhH#transition-activities", "label": "Exclusive Collaboration Agreement (Eikon Therapeutics, Inc.)", "score": 36.3511293634, "published": true}], "size": 2, "hash": "ea14fa7274ea3a71f16e04424bd1bbd0", "id": 8}, {"snippet_links": [], "snippet": "shall have the meaning given to such term in Section 7.4(m).", "samples": [{"hash": "5TAHaCYVu45", "uri": "/contracts/5TAHaCYVu45#transition-activities", "label": "Asset Purchase Agreement (Extreme Networks Inc)", "score": 27.704996109, "published": true}], "size": 1, "hash": "111564cf7f98e3a2380132936e3b1c02", "id": 9}, {"snippet_links": [{"key": "the-service-provider", "type": "definition", "offset": [21, 41]}], "snippet": "means, collectively, the Service Provider Transition Activities and the OLG Transition Activities.", "samples": [{"hash": "jba55GowkS5", "uri": "/contracts/jba55GowkS5#transition-activities", "label": "Transition and Asset Purchase Agreement (Mohegan Tribal Gaming Authority)", "score": 30.4483222961, "published": true}], "size": 1, "hash": "a5580233eb68b91e410df169e98ec5d2", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIedHJhbnNpdGlvbi1hY3Rpdml0aWVzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Transition Activities", "snippet": "has the meaning set forth in Section 5.3.2 (Transition).", "size": 61, "id": "transition-activities", "examples": ["The Server Installation Fee is only applicable for new Server installations as a result of growth and not applicable for Servers installed as a result of Refresh, <strong>Transition Activities</strong> or Transformation Activities including stabilization, seed Equipment, or Server consolidation.", "Genzyme shall reimburse Voyager on a quarterly basis for Development FTE Costs, Out-of-Pocket Costs and Cost of Goods incurred by Voyager in the performance of <strong>Transition Activities</strong>, within [***] after receipt by Genzyme of an invoice for such amounts from Voyager.", "During the period commencing after the completion of the T1 <strong>Transition Activities</strong> and ending upon Regulatory Approval of the first T1 Licensed Product, Novartis may request that Surface reasonably make available for consultation regarding the Development of T1 Antibody Candidates and T1 Licensed Products certain of its employees engaged in Research and Development activities with respect to such T1 Antibody Candidates and T1 Licensed Products.", "Without limiting the generality of the foregoing, and without limiting the delivery and provision of Licensed Know-How, MedImmune will promptly deliver, make available or otherwise provide to Licensee and Licensee Representatives, Licensed Know-How and the Purchased Assets in accordance with the requirements and timelines set forth in the <strong>Transition Activities</strong>.", "The Parties hereby agree that the <strong>Transition Activities</strong> shall be provided at MedImmune\u2019s sole expense for up to [***] hours as set out in Schedule 1.104 and/or theTransition Services Agreement, and thereafter at Licensee\u2019s sole expense (including MedImmune\u2019s employee costs at the FTE Rate).", "During the period commencing after the completion of the Global <strong>Transition Activities</strong> and ending upon Regulatory Approval of the first Global Licensed Product, Novartis may request that Surface reasonably make available for consultation regarding the Development of Global CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH \u201c[***]\u201d.", "While Akcea is providing Post-Termination <strong>Transition Activities</strong> under the Termination Transition Plan, Akcea and Ionis will agree on talking points and a communication plan to customers, specialty pharmacies, physicians, regulatory authorities, patient advocacy groups, and clinical study investigators, and Akcea will make all such communications to such entities in accordance with such talking points and communication plan.", "Cause to be maintained a Consolidated Fixed Charge Coverage Ratio as of the end of each Fiscal Quarter, (a) beginning with the Fiscal Quarter ending December 31, 2021, of not less than 1.25 to 1.00 through and including March 31, 2024 and (b) beginning with the Fiscal Quarter ending JuneSeptember 30, 2025 and thereafter, of not less than 1.50 to 1.00.", "By no later than the Final Transition Deadline, Alnylam shall deliver the Certification (or, if such Certification was previously delivered by the Initial Transition Deadline, an updated Certification with respect to any Uncompleted <strong>Transition Activities</strong>), to Genzyme; provided however, that Alnylam shall include any qualifications or limitations that are applicable to the Certification as needed to ensure that the Certification is true and correct.", "If Ionis so requests Post-Termination <strong>Transition Activities</strong>, then, without limiting the provisions of Section 10.4.2, the Parties will mutually agree upon a transition plan for Akcea to perform the Post-Termination <strong>Transition Activities</strong> including delivery and transition dates for such activities (the \u201cTermination Transition Plan\u201d)."], "related": [["collaboration-activities", "Collaboration Activities", "Collaboration Activities"], ["development-activities", "Development Activities", "Development Activities"], ["construction-activities", "Construction Activities", "Construction Activities"], ["transition", "Transition", "Transition"], ["medical-affairs-activities", "Medical Affairs Activities", "Medical Affairs Activities"]], "related_snippets": [], "updated": "2026-01-11T05:42:16+00:00"}, "json": true, "cursor": ""}}